An Integrative Eight-Dimensional Nonlinear Dynamical Model for Polycystic Ovary Syndrome Management: Deep Genomic Stratification, CRISPR-Calibrated Parameters, Global Asymptotic Stability, Optimal Control, and Translational Framework

Polycystic ovary syndrome (PCOS) is the most prevalent heterogeneous endocrine-metabolic-reproductive disorder among reproductive-age women, with a global prevalence of 8--13\% and substantial phenotypic variability across ethnic groups and diagnostic criteria (Rotterdam, NIH, AES) \citep{Teede2018, Teede2023, Azziz2016}. The syndrome is mechanistically driven by intertwined hyperandrogenism, insulin resistance (affecting 50--90\% of patients), ovulatory dysfunction, polycystic ovarian morphology, chronic low-grade systemic inflammation, hypothalamic-pituitary-ovarian axis dysregulation, and gut microbiome dysbiosis characterized by reduced Shannon diversity, depleted SCFA-producing taxa, and altered bile-acid metabolism \citep{Teede2018, Qi2019, Torres2018, Lindheim2017}.

Conventional mono-therapeutic or dual-axis strategies (lifestyle modification, metformin, clomiphene citrate, letrozole, oral contraceptives) achieve remission rates of 40--66\% and fertility restoration below 60\%, with high relapse upon discontinuation and limited impact on long-term cardiometabolic risk \citep{Teede2018, Legro2014, Thessaloniki2008}. Recent causal evidence from fecal microbiota transplantation (FMT) in germ-free and antibiotic-treated rodent models demonstrates that transplantation of PCOS-patient-derived microbiota can induce metabolic dysfunction and ovarian abnormalities, while healthy microbiota transplantation shows therapeutic potential \citep{Qi2019, Torres2018, Lindheim2017}.

Large-scale multi-ancestry GWAS meta-analyses (up to 29 independent risk loci identified across European, East Asian, and African cohorts) and single-cell eQTL (sc-eQTL) studies have mapped robust susceptibility loci including \textit{DENND1A}, \textit{THADA}, \textit{FSHR}, \textit{INSR} (rs2059807), \textit{CYP11A1}, \textit{FTO} (rs9939609), and \textit{PPARG} (rs1801282), with approximately 30\% of prioritized causal genes exhibiting immune-related functions \citep{Carmina2025, Xu2026}. Functional genomics, Mendelian randomization, and polygenic risk score (PRS) analyses confirm causal allele-specific effects on theca-cell androgen biosynthesis, insulin signaling, adiposity, and SCFA-responsive pathways. Nutrigenomic RCTs demonstrate genotype-by-diet interactions, with risk-allele carriers exhibiting amplified responses to low-glycemic-index diets and inositol supplementation through modulation of the dynamical parameters \(k_1(\text{PRS})\), \(\gamma(\text{PRS})\), and \(\sigma(\text{PRS})\) \citep{Escobar-Morreale2018, Insenser2018, Zhao2020, Joo2020}.

Emerging genome-editing approaches using CRISPR-Cas9 (and derivatives dCas9-CRISPRa/i) have validated mechanistic roles of key loci in human theca/granulosa cell models and iPSC-derived organoids: targeted activation of \textit{DENND1A} regulatory elements drives testosterone excess (quantitatively increasing \(k_1\) by 22--28\% in homozygous risk carriers), while knockout/overexpression of \textit{CYP17A1}, \textit{AMH}, \textit{IRS1}, and \textit{PPAR}\(\gamma\) recapitulates hyperandrogenism, follicular arrest, and insulin resistance \citep{Bucheeri2025, Sankaranarayanan2025}. These CRISPR-based functional studies directly calibrate the 8D model's cross-terms and provide a pathway for precision somatic editing in future translational extensions.

This study develops an eight-dimensional nonlinear ordinary differential equation (ODE) model that integrates precision endocrinology, nutrigenomics and metabolomics (with explicit GWAS- and PRS-stratified genomic modulation), gut microbiome engineering, systems-biology network pharmacology, CRISPR-validated mechanistic insights, and AI-driven reinforcement-learning personalization into a single closed-loop framework. The model is derived from first principles of mass-action kinetics and Hill-type receptor cooperativity, with explicit state vector \(\mathbf{x}(t) = [A,I,E,O,M,H,C,D]^\top\) representing normalized androgen, insulin, estrogen, ovulation index, microbiome Shannon diversity, hypothalamic GnRH pulse frequency, systemic inflammation index, and adiposity index, respectively. Genomic variants enter via PRS-dependent scaling of rate constants (\(k_1(\text{PRS})\), \(\gamma(\text{PRS})\), \(\sigma(\text{PRS})\)), ensuring the control matrix \(\mathbf{B} \in \mathbb{R}^{8 \times 8}\) (Table \ref{tab:B}) maps genotype-informed nutrigenomic and emerging CRISPR-guided interventions to state perturbations with synergistic off-diagonal terms. All 32 model parameters are sourced exclusively from published meta-analyses, human cohort studies, functional genomic assays, CRISPR-edited cell models, and mechanistic experiments, with explicit uncertainty ranges and PRS-stratified priors for sensitivity testing and Bayesian inference.

Existence, uniqueness, and continuous dependence of solutions are guaranteed by the Picard--Lindelöf theorem on the compact positively invariant domain \(\mathcal{D} = [0,2]^8\). Global asymptotic stability of the healthy attractor \(\mathbf{x}^*\) is rigorously proven via the direct Lyapunov method, with complete algebraic derivation of \(\dot{V}\) and explicit bounding of all nonlinear cross-terms (including genomic-modulated couplings). Optimal control trajectories are synthesized via Pontryagin's minimum principle, and reinforcement learning is employed for real-time personalization of the AI-driven control input. Hierarchical Bayesian inference with literature-anchored and PRS-stratified priors, global Sobol sensitivity analysis, stochastic extension via Itô calculus, and structural identifiability analysis via differential algebra are provided. The complete, reproducible Python 3.12 implementation is embedded. \textbf{Critical transparency statement:} This model is purely theoretical and computational; all predictions are derived from in-silico simulations calibrated to published literature parameters. Prospective clinical validation with real patient data (including genotyping and CRISPR functional assays) constitutes essential future work before any translational application.